You are here

IMGN632

After weathering failure, rejection and layoffs, ImmunoGen touts a new 'breakthrough' drug in its comeback plan

Endpoints

Mon, 10/5/20 - 10:57 am

blastic plasmacytoid dendritic cell neoplasm

A delicate balancing act for Immunogen

EP Vantage

Tue, 05/21/19 - 09:33 am

mirvetuximab soravtansin

Jazz Pharmaceuticals

9 Notable Biotechs Presenting At This Year's ASH Meeting

Yahoo

Tue, 11/7/17 - 09:56 am

Ziopharm Oncology

Spark Therapeutics

Juno Therapeutics